Advertisement
09/14/2021

AAM makes 2 key appointments

The organization is welcoming Polly Webster as vice president of federal affairs and Erik Komendant as senior vice president of government affairs.
Sandra Levy
Senior Editor
Sandra Levy profile picture

The Association for Accessible Medicines is welcoming two new executives.

Polly Webster is joining the Association for Accessible Medicines as vice president, federal affairs. As a senior strategist and lobbyist, she will represent AAM and its member companies’ interests before Congress and the White House. She will develop short- and long-term goals in support of the federal affairs strategy and lead the promotion of AAM’s objectives through advocacy while preserving and enhancing the association’s important relationships on Capitol Hill.

[Read more: AAM commends President Biden's 'Build Back Better Plan]

“We are excited to welcome Polly to the team and to be able to bring someone of her caliber to AAM,” said Erik Komendant, senior vice president of government affairs. “Polly’s expertise in prescription drug policy, experience working in the House and Senate, and ability to work collaboratively across a diverse set of stakeholders will help advance AAM’s priorities to increase patient access to generic and biosimilar medicines.”

Webster was previously at Kaiser Permanente, where as Principal Policy Advisor, Government Relations, she led the organization’s work on prescription drug policy and regulations. She also served as Health Policy Director for Congresswoman Diana DeGette, D-Colo., Health Policy Fellow on the Democratic Senate Committee on Finance and with Senator Jay Rockefeller, D-W.Va.

Webster received her Bachelors from Denison University, her Master of Public Health from The George Washington University and her law degree from Georgetown University.

[Read more: AAM supports Biden administration's 100-day supply chain review]

Scott Kuzner is joining AAM as senior director of sciences and regulatory affairs. He will be engaged in the development and oversight of AAM’s Sciences and Regulatory Affairs initiatives. Kuzner comes to AAM from the United States Pharmacopeial Convention, where he served for more than a decade with increasing responsibility, most recently as Director, Board and Convention Operations.

“As we wrap up GDUFA and BsUFA negotiations and begin the legislative review and approval processes, and move into the user fee implementation phases, this is a great time to bring Scott on board,” said AAM senior vice president, sciences and regulatory affairs, David Gaugh. We welcome Scott to our team and look forward to our continued strong collaboration with USP."

Kuzner holds a BA, MA and PhD from the University of Maryland.

 

 

Advertisement
Advertisement